-
公开(公告)号：CZ300737B6
公开(公告)日：2009-07-29
申请号：CZ2002837
申请日：2001-06-05
Applicant: UCB PHARMA SA
Inventor： ATHWAL DILJEET SINGH , BROWN DEREK THOMAS , WEIR ANDREW NEIL CHARLES , POPPLEWELL ANDREW GEORGE , CHAPMAN ANDREW PAUL , KING DAVID JOHN
IPC: C12N15/09 , C12N15/13 , A61K39/395 , A61K47/48 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/24 , C07K16/46 , C07K19/00 , C12N1/21 , C12N15/62 , C12N15/70 , C12P21/02 , C12P21/08
Abstract: Molekula protilátky specifická pro humánní TNF.alfa., která obsahuje lehký retezec a težký retezec, kde tento lehký retezec obsahuje variabilní úsek lehkého retezce hTNF40-gL1 (SEKV. ID. C. 8) a težký retezec obsahuje variabilní úsek težkého retezce gh3hTNF40.4 (SEKV. ID. C. 11), a zpusob její prípravy. Sloucenina obsahující tuto molekulu protilátky, která obsahuje lehký retezec tvorený sekvencí uvedenou zde jako SEKV. ID. C. 113 a težký retezec tvorený sekvencí uvedenou zde jako SEKV. ID. C. 115, mající na jednom ze svých cysteinových zbytku na C-konci težkého retezce navázanou skupinu odvozenou z lysyl-maleinimidové skupiny, kde každá ze dvou aminových skupin lysylových zbytku má kovalentne navázaný methoxypoly(ethylenglykol)ový zbytek o molekulové hmotnosti asi 20 000 Da, každý v aminoskupine lysylu, pricemž celková molekulová hmotnost methoxypoly(ethylenglykol)ových zbytku je asi 40 000 Da. Sekvence DNA kódující težký a/nebo lehký retezec molekuly protilátky, klonovací nebo expresní vektor a hostitelský bunka transformovaná tímto vektorem. Terapeutická nebo diagnostická kompozice a použití molekuly protilátky pro lécení revmatoidní artritidy, osteoartritidy, Crohnovy nemoci nebo psoriázy.
-
公开(公告)号：CA2681530A1
公开(公告)日：2008-10-02
申请号：CA2681530
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： TAYLOR FREDERICK R , BURKLY LINDA C , BROWN DEREK THOMAS , ADAMS RALPH , TYSON KERRY LOUISE , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , SU LIHE , HSU YEN-MING , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) p rotein. This invention also provides a chimeric, humanized or fully human an tibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy cha in sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding protein s of this invention may elicit reduced effector function relative to a secon d anti-CD154 antibody. CD154 binding proteins of this invention are useful i n diagnostic and therapeutic methods, such as in the treatment and preventio n of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
-
23.发明专利
公开(公告)号：CA2707766A1
公开(公告)日：2001-12-13
申请号：CA2707766
申请日：2001-06-05
Applicant: UCB PHARMA SA
Inventor： ATHWAL DILJEET SINGH , BROWN DEREK THOMAS , WEIR ANDREW NEIL , POPPLEWELL ANDREW GEORGE , CHAPMAN ANDREW PAUL , KING DAVID JOHN
IPC: C12N15/09 , C12N15/63 , A61K39/395 , A61K47/48 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/24 , C07K16/46 , C12N1/21 , C12N15/13 , C12P21/02 , C12P21/08
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF± There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF±
-
24.发明专利
公开(公告)号：CY1118220T1
公开(公告)日：2017-06-28
申请号：CY161101159
申请日：2016-11-10
Applicant: UCB PHARMA SA
Inventor： ATHWAL DILJEET SINGH , BROWN DEREK THOMAS , WEIR ANDREW NEIL CHARLES , POPPLEWELL ANDREW GEORGE , CHAPMAN ANDREW PAUL , KING DAVID JOHN
IPC: C12N15/09 , C12N15/13 , A61K39/395 , A61K47/48 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/24 , C07K16/46 , C07K19/00 , C12N1/21 , C12N15/62 , C12N15/70 , C12P21/02 , C12P21/08
Abstract: Περιγράφονταιμόριααντισωμάτωνπουπεριέχουντουλάχιστονένα CDR προερχόμενοαπόμονοκλωνικάαντισώματαποντικού, μεειδικότηταπροςτονανθρώπινο TNFa. Περιγράφεταιεπίσηςένααντίσωμαμεμοσχευμένα CDR στοοποίοτουλάχιστονέναεκτων CDR είναιέναυβριδικό CDR. Περιγράφονταιεπιπλέοναλληλουχίες DNA πουκωδικοποιούντιςαλυσίδεςτωναντισωμάτων, φορείς, μετασχηματισμένακύτταραξενιστέςκαιχρήσειςτωναντισωμάτωνστηναντιμετώπισηνοσημάτωνπουεξαρτώνταιαπότον TNFa.
-
公开(公告)号：CA2681530C
公开(公告)日：2017-03-28
申请号：CA2681530
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C12N15/13 , A61K39/395 , C07K16/28 , C12N15/63
Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody.
-
Patent Agency Ranking26.发明专利
公开(公告)号：SK288343B6
公开(公告)日：2016-04-01
申请号：SK3152002
申请日：2001-06-05
Applicant: UCB PHARMA SA
Inventor： ATHWAL DILJEET SINGH , BROWN DEREK THOMAS , WEIR ANDREW NEIL CHARLES , POPPLEWELL ANDREW GEORGE , CHAPMAN ANDREW PAUL , KING DAVID JOHN
IPC: A61K39/395 , C07K16/24 , A61K47/48 , C12N15/09 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/46 , C07K19/00 , C12N1/21 , C12N15/13 , C12N15/62 , C12N15/70 , C12P21/02 , C12P21/08
Abstract: Predložený vynález sa týka protilátkových molekúl, ktoré sú špecifické pre antigénne determinanty nádorového nekrotického faktoru alfa (TNF?) a ktoré obsahujú aspoň jeden úsek CDR z myšej monoklonálnej protilátky. Predložený vynález sa tiež týka tzv. CDR-očkovaných protilátok, kde aspoň jeden z úsekov CDR je hybridný CDR. Ďalej je predmetom DNA sekvencia kódujúca reťazce molekuly protilátky a tiež vektory a transformované hostiteľské bunky. Vynález sa ďalej týka terapeutického využitia protilátkových molekúl na liečenie chorôb sprostredkovaných TNF?.
-
公开(公告)号：PL218516B1
公开(公告)日：2014-12-31
申请号：PL39935101
申请日：2001-06-05
Applicant: UCB PHARMA SA
-
公开(公告)号：BRPI0809042A2
公开(公告)日：2014-09-16
申请号：BRPI0809042
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: This invention provides binding proteins, including antibodies, antibody derivates and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivate or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
-
公开(公告)号：ES2374068T3
公开(公告)日：2012-02-13
申请号：ES03778577
申请日：2003-12-01
Applicant: UCB PHARMA SA
Inventor： BROWN DEREK THOMAS , BUTLER LISA , CROMIE KAREN DOROTHY , GRIFFITHS MERYN RUTH , LAWSON ALASTAIR D G , LIGHTWOOD DANIEL JOHN
IPC: G01N33/52 , C07K16/24 , G01N33/569 , G01N33/58 , G01N33/68
Abstract: Un ensayo homogéneo in vitro para identificar una célula productora de anticuerpos que produce un anticuerpo que se une a un antígeno seleccionado que comprende: a) proporcionar una población de células productoras de anticuerpos; b) incubar sobre un portaobjetos de microscopio dicha población de células productoras de anticuerpos con un antígeno seleccionado conjugado con una perla o acoplado a un eritrocito, o antígeno expresado sobre la superficie de un célula, y un anticuerpo anti-anticuerpo marcado, en el que dicho anticuerpo anti-anticuerpo puede distinguir células que producen un anticuerpo que se une al antígeno seleccionado de las células que no lo hacen y en el que el anticuerpo anti-anticuerpo marcado se marca con un conjugado fluorescente; y c) sin necesidad de retirar anticuerpos anti-anticuerpo marcados no unidos, identificar una célula productora de anticuerpos capaz de producir un anticuerpo que se une al antígeno seleccionado detectando el incremento en la concentración de anticuerpos anti-anticuerpo marcados que rodean la célula usando un microscopio.
-
公开(公告)号：AT451460T
公开(公告)日：2009-12-15
申请号：AT01934209
申请日：2001-06-05
Applicant: UCB PHARMA SA
Inventor： ATHWAL DILJEET SINGH , BROWN DEREK THOMAS , WEIR ANDREW NEIL CHARLES , POPPLEWELL ANDREW GEORGE , CHAPMAN ANDREW PAUL , KING DAVID JOHN
IPC: C12N15/09 , C12N15/13 , A61K39/395 , A61K47/48 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/24 , C07K16/46 , C07K19/00 , C12N1/21 , C12N15/62 , C12N15/70 , C12P21/02 , C12P21/08
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF± There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF±
-
-
-
-
-
-
-
-
-
Search Results
59
records
(took 0.024 seconds)
